Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jessica MacSuga

Podiatrist Davison, MI Doctor of Podiatric Medicine

NPI 1174941116 CMS profile 2784170

605 S State Rd, Davison, MI 48423

Open in the dashboard

General payments

$10,160

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica MacSuga of Davison, MI is reported in the CMS Open Payments database as having received $10,160 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,192 16
2024 General $1,895 31
2023 General $1,188 23
2022 General $925 21
2021 General $969 15
2020 General $1,716 27
2019 General $2,276 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica MacSuga
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Jessica MacSuga were reported at $1,192. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Jessica MacSuga Podiatrist median Middle half National median
2019 $2,276 $196 $72–$601 $163
2020 $1,716 $118 $38–$335 $114
2021 $969 $169 $57–$573 $132
2022 $925 $220 $74–$782 $149
2023 $1,188 $208 $71–$635 $160
2024 $1,895 $237 $87–$681 $164
2025 $1,192 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,046 39 payments
  2. Arthrex, Inc. $2,283 8 payments
  3. Smith+Nephew, Inc. $907 38 payments
  4. Medwest Associates $834 3 payments
  5. DePuy Synthes Sales Inc. $522 7 payments
  6. Paragon 28, Inc. $415 9 payments
  7. Bioventus LLC $371 11 payments
  8. Horizon Therapeutics plc $299 7 payments
  9. Cardiovascular Systems Inc. $243 4 payments
  10. Treace Medical Concepts, Inc. $183 2 payments
  11. Other $1,058 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,585 139 payments
  2. Education $2,101 5 payments
  3. Travel and Lodging $1,474 6 payments
Products named General payments · program years 2019–2025
  1. ORTHOLOC 2 LAPIFUSE $483 5 payments
  2. ORTHOLOC 3DI $416 4 payments
  3. PRIME SERIES $382 1 payment
  4. N/A $363 3 payments
  5. PROSTEP MICA $312 4 payments
  6. GRAFIX PL $293 5 payments
  7. ALLOMATRIX $288 3 payments
  8. ACTISHIELD $284 2 payments
  9. KRYSTEXXA $273 6 payments
  10. EASYFUSE $220 3 payments
  11. Other $5,078 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

506

Median for Podiatry: 160

Drug cost

$13,675

Median for Podiatry: $2,368

Branded share of claims

44.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 21 $9,102
Ammonium Lactate Generic 54 $1,094
Cephalexin Generic 30 $865
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 157 $828
Ketoconazole Generic 39 $554
Terbinafine Hcl Generic 15 $355
Ciclopirox Generic 15 $265
Silver Sulfadiazine Generic 20 $108
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 37 $99
Clindamycin Hcl Generic 11 $84

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$104,229

Of which drugs: $42

Medicare patients

407

Average age 74

Services billed

1,769

213 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 55%
Chronic kidney disease 38%
Ischemic heart disease 36%
Heart failure 27%
Atrial fibrillation 27%
Depression 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 57 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record